Global Primary Biliary Cholangitis Market Growth Prospects and Strategic Opportunities Through 2029

Global Primary Biliary Cholangitis Market

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Primary Biliary Cholangitis Market Expected To Grow In Terms Of Size?

The market size for primary biliary cholangitis has seen robust growth in the past few years. An expansion from $0.98 billion in 2024 to an estimated $1.06 billion in 2025 is expected, with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this rise during the historical period include heightened awareness about the disease, increment in global healthcare spending, strategic partnerships within the healthcare sector, emphasis on patient advocacy, and government health initiatives aimed at liver health.

Expected to witness significant growth in the coming years, the market size for primary biliary cholangitis is projected to reach $1.47 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%. Factors contributing to growth during the forecast period include the advancement in biomarker research, worldwide efforts to manage rare diseases, increased collaboration in clinical trials, focus on patient-centered healthcare, and a rising demand for liver transplants. The forecast period will also see trends such as progress in biomarker research, a growing emphasis on non-invasive diagnostic methods, a research focus on immunomodulatory treatments, the incorporation of artificial intelligence (AI), patient-reported results in clinical trials, the use of telemedicine for patient management, a focus on combination treatments, as well as the emergence of therapies targeting fibrosis.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Key Factors Are Fueling Growth In The Primary Biliary Cholangitis Market?

The upward trend in smoking is anticipated to boost the expansion of the primary biliary cholangitis market in the future. The term smoking denotes the process of inhaling and exhaling smoke from burned tobacco or other materials. It’s well-known that smoking is a significant risk factor for liver diseases, such as PBC, meaning higher smoking rates can result in a greater number of people seeking treatment for liver-related conditions. For example, in July 2023, as per Statistics Canada, a governmental agency from Canada, there was a 2.2% increase in cigarette production as compared to June 2023 in the country. There was also a 2.6% boost in cigarette sales in June, with sales hitting 1.4 billion units compared to May. Therefore, the surging smoking incidences will contribute to the growth of the primary biliary cholangitis market.

How Is The Primary Biliary Cholangitis Market Categorized Across Applications And Types?

The primary biliary cholangitismarket covered in this report is segmented –

1) By Treatment Type: Drugs; Liver Transplantation

2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses

3) By End-Users: Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant

How Are Industry Trends Steering The Expansion Of The Primary Biliary Cholangitis Market?

Primary biliary cholangitis market players are concentrating their efforts on the creation of unique and effective treatments for the condition, like orphan drugs that are a blend of obeticholic acid (OCA) and bezafibrates, aiming for market monopoly. The union of OCA and bezafibrate is intended to provide a more holistically efficient solution to primary biliary cholangitis management, potentially enhancing the lives of those impacted by this uncommon ailment. For example, in May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical company based in the US, was granted orphan drug status by the FDA for a potential PBC treatment combo of OCA and a PPAR agonist, bezafibrate, with obeticholic acid (marketed under the name Ocaliva) having been approved for PBC treatment in the US.

Which Firms Are Making The Biggest Impact In The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Region Holds The Greatest Opportunity For Primary Biliary Cholangitis Market Expansion?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2025, By The Business Research Company

Gastroesophageal Reflux Disease Gerd Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Migraine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/migraine-global-market-report

Myelodysplastic Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model